Conference Proceedings

KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER /HER2−breast cancer

F Cardoso, A Bardia, F André, DW Cescon, H McArthur, M Telli, S Loi, J Cortes, P Schmid, N Harbeck, C Denkert, C Jackisch, L Jia, K Hirshfield, V Karantza

Annals of Oncology | Elsevier BV | Published : 2019